Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial

Grzegorz S. Nowakowski, Wolfgang Willenbacher, Richard Greil, Thomas S. Larsen, Krish Patel, Ulrich Jäger, Robert F. Manges, Lorenz Trümper, Hele Everaus, Nagesh Kalakonda, Peter Brown, Judit Meszaros Jørgensen, David Cunningham, Justine Dell’Aringa, Brian Fox, Neus Domper Rubio, Nurgul Kilavuz, Marie Laure Casadebaig, Oliver Manzke, Javier Munoz

Research output: Contribution to journalArticlepeer-review

16 Scopus citations

Fingerprint

Dive into the research topics of 'Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Neuroscience

Immunology and Microbiology